Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Building Capacity to Reduce Stroke in Children With Sickle Cell Anemia in the Dominican Republic: The SACRED Trial
source: Blood Advances
year: 2018
authors: Luisanna M. Sánchez, Rosa M. Nieves, Teresa Latham, Susan Stuber, Judy R. Luden, Gabriela S. Urcuyo, Melissa E. Berges, Carla Florencio, Carla Gonzalez, Paola Del Villar, Adam Lane, William Schultz, Neelum Jeste, Rafael Mena, Russell E. Ware
summary/abstract:The prevalence of sickle cell anemia (SCA) in the Dominican Republic is approximately 4 times that in the United States.
In the pediatric sickle cell clinic at Hospital Infantil Dr. Robert Reid Cabral (HIRRC) located in the capital city of Santo Domingo, Dominican Republic, 5% to 10% of children with HbSS (homozygous for hemoglobin S) develop primary stroke, with substantial morbidity and mortality.
Transcranial Doppler (TCD) ultrasonography has been shown to effectively identify the risk for primary stroke in the United States but is not routinely accessible or available in the Dominican Republic.
Hydroxyurea is a potent disease-modifying therapy for SCA that can reduce TCD velocities and prevent conversion of conditional to abnormal velocities. Hydroxyurea is available in the Dominican Republic, but health care providers do not have experience with dosing, and most families cannot afford the cost.
organization: Cincinnati Children's Hospital Medical Center, USA; Hospital Infantil Dr. Robert Reid Cabral, Dominican Republic; Centro de Obstetricia y Ginecología, Dominican RepublicDOI: 10.1182/bloodadvances.2018GS110818.
read more
+myBinderRelated Content
-
Effects of Hydroxyurea (HU) on Neurocognitive Performance in Children With Sickle Cell Disease: A Prospective TrialSickle cell anemia is associated with pr...
-
Don’t Let Sickle Cell Disease Limit Youhttps://www.onescdvoice.com/wp-content/u...
-
Hydroxyurea Treatment for Sickle Cell Disease – Children’s National Health SystemAt Children’s National, we understand ...
-
SCD Patients Receiving Hydroxyurea in the U.S. Still Face Many ChallengesPeople with sickle cell disease (SCD) tr...
-
Sickle Cell Disease Research Shows Progress in Preventing Related Complications and DeathStudies aim to limit pain crises, preven...
-
How to Talk to Your Child About Hydroxyureahttps://www.youtube.com/watch?v=_apTt2j0...
-
ADDMEDICA receives FDA-approval for orphan drug Siklos®, first and sole hydroxyurea-based treatment for paediatric ...ADDMEDICA has announced that the...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.